CA3153630A1 - Stable, concentrated radionuclide complex solutions - Google Patents
Stable, concentrated radionuclide complex solutions Download PDFInfo
- Publication number
- CA3153630A1 CA3153630A1 CA3153630A CA3153630A CA3153630A1 CA 3153630 A1 CA3153630 A1 CA 3153630A1 CA 3153630 A CA3153630 A CA 3153630A CA 3153630 A CA3153630 A CA 3153630A CA 3153630 A1 CA3153630 A1 CA 3153630A1
- Authority
- CA
- Canada
- Prior art keywords
- stabilizer
- aqueous solution
- solution
- pharmaceutical aqueous
- concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
- A61K51/121—Solutions, i.e. homogeneous liquid formulation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
- A61K51/048—DTPA (diethylenetriamine tetraacetic acid)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/083—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being octreotide or a somatostatin-receptor-binding peptide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IBPCT/IB2018/055575 | 2018-07-25 | ||
| US16/045,484 | 2018-07-25 | ||
| US16/045,484 US20200030465A1 (en) | 2018-07-25 | 2018-07-25 | Stable, concentrated radionuclide complex solutions |
| PCT/IB2018/055575 WO2020021310A1 (en) | 2018-07-25 | 2018-07-25 | Stable, concentrated radionuclide complex solutions |
| PCT/IB2018/057415 WO2020021322A1 (en) | 2018-07-25 | 2018-09-25 | Stable, concentrated radionuclide complex solutions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3153630A1 true CA3153630A1 (en) | 2020-01-30 |
Family
ID=63794577
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3153630A Pending CA3153630A1 (en) | 2018-07-25 | 2018-09-25 | Stable, concentrated radionuclide complex solutions |
Country Status (23)
| Country | Link |
|---|---|
| EP (7) | EP4640241A3 (https=) |
| JP (3) | JP7402218B2 (https=) |
| KR (4) | KR102865113B1 (https=) |
| CN (5) | CN120860271A (https=) |
| AU (6) | AU2018433575B2 (https=) |
| BR (1) | BR112021001148A2 (https=) |
| CA (1) | CA3153630A1 (https=) |
| CO (1) | CO2021000506A2 (https=) |
| DE (3) | DE202018006567U1 (https=) |
| DK (6) | DK4545101T3 (https=) |
| ES (4) | ES3064434T3 (https=) |
| FI (6) | FI4541379T3 (https=) |
| HR (6) | HRP20260338T1 (https=) |
| HU (1) | HUE072720T2 (https=) |
| IL (4) | IL319541B2 (https=) |
| LT (6) | LT4541381T (https=) |
| MX (2) | MX2021000805A (https=) |
| PL (5) | PL3826686T3 (https=) |
| PT (6) | PT4541381T (https=) |
| RS (5) | RS67667B1 (https=) |
| SG (1) | SG11202100645XA (https=) |
| SI (5) | SI4545101T1 (https=) |
| WO (1) | WO2020021322A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11541134B1 (en) | 2021-08-02 | 2023-01-03 | Rayzebio, Inc. | Stabilized compositions of radionuclides and uses thereof |
| EP4442285A1 (en) * | 2021-11-30 | 2024-10-09 | Nihon Medi-Physics Co., Ltd. | Stabilized radiopharmaceutical composition |
| US20260053959A1 (en) * | 2022-02-04 | 2026-02-26 | Advanced Accelerator Applications | Methods for large scale synthesis of radionuclide complexes |
| CN114404618A (zh) * | 2022-03-28 | 2022-04-29 | 北京先通国际医药科技股份有限公司 | 放射性药物水溶液及其用途 |
| CN114404619A (zh) * | 2022-03-28 | 2022-04-29 | 北京先通国际医药科技股份有限公司 | 放射性药物水溶液及其制备方法和用途 |
| CN116920129A (zh) * | 2022-04-02 | 2023-10-24 | 北京先通国际医药科技股份有限公司 | 放射性药物水溶液及其制备方法和用途 |
| US20260102526A1 (en) * | 2024-06-27 | 2026-04-16 | Curium Us Llc | 177lutetium-dota-tate formulations |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2779780A (en) | 1955-03-01 | 1957-01-29 | Du Pont | 1, 4-diamino-2, 3-dicyano-1, 4-bis (substituted mercapto) butadienes and their preparation |
| US4261989A (en) | 1979-02-19 | 1981-04-14 | Kaken Chemical Co. Ltd. | Geldanamycin derivatives and antitumor drug |
| EP0647450A1 (en) | 1993-09-09 | 1995-04-12 | BEHRINGWERKE Aktiengesellschaft | Improved prodrugs for enzyme mediated activation |
| US6066309A (en) * | 1996-02-02 | 2000-05-23 | Rhomed Incorporated | Post-labeling stabilization of radiolabeled proteins and peptides |
| EP1143957A3 (en) | 1998-12-16 | 2002-02-27 | Warner-Lambert Company | Treatment of arthritis with mek inhibitors |
| JP3811775B2 (ja) | 2000-07-19 | 2006-08-23 | ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー | ４−ヨードフェニルアミノベンズヒドロキサム酸の酸素化エステル |
| US6995162B2 (en) | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
| PT1478648E (pt) | 2002-02-01 | 2014-07-15 | Ariad Pharma Inc | Compostos contendo fósforo e suas utilizações |
| CN1653059A (zh) | 2002-03-08 | 2005-08-10 | 卫材株式会社 | 用作医药品的大环化合物 |
| KR100984595B1 (ko) | 2002-03-13 | 2010-09-30 | 어레이 바이오파마 인크. | Ｍｅｋ 억제제로서의 ｎ3 알킬화 벤즈이미다졸 유도체 |
| TWI275390B (en) | 2002-04-30 | 2007-03-11 | Wyeth Corp | Process for the preparation of 7-substituted-3- quinolinecarbonitriles |
| JP5139678B2 (ja) * | 2003-07-24 | 2013-02-06 | ブラッコ・イメージング・ソシエタ・ペル・アチオニ | 安定な放射性医薬品組成物およびその製法 |
| CA2618218C (en) | 2005-07-21 | 2015-06-30 | Ardea Biosciences, Inc. | N-(arylamino)-sulfonamide inhibitors of mek |
| WO2008009444A1 (en) | 2006-07-19 | 2008-01-24 | Van Dulmen, Adrianus, A. | Use of ethanol for stabilizing a single-vial liquid formulation of a radiolabeled peptide |
| CA3042737A1 (en) * | 2016-11-04 | 2018-05-11 | Clarity Pharmaceuticals Pty Ltd | Formulations for radiotherapy and diagnostic imaging |
| US10596276B2 (en) | 2018-07-25 | 2020-03-24 | Advanced Accelerator Applications (Italy) S.R.L. | Stable, concentrated radionuclide complex solutions |
-
2018
- 2018-09-25 LT LTEP25162403.7T patent/LT4541381T/lt unknown
- 2018-09-25 FI FIEP25162390.6T patent/FI4541379T3/fi active
- 2018-09-25 HR HRP20260338TT patent/HRP20260338T1/hr unknown
- 2018-09-25 CN CN202511294583.8A patent/CN120860271A/zh active Pending
- 2018-09-25 EP EP25200826.3A patent/EP4640241A3/en active Pending
- 2018-09-25 KR KR1020247006883A patent/KR102865113B1/ko active Active
- 2018-09-25 AU AU2018433575A patent/AU2018433575B2/en active Active
- 2018-09-25 EP EP25162403.7A patent/EP4541381B1/en active Active
- 2018-09-25 HU HUE18783136A patent/HUE072720T2/hu unknown
- 2018-09-25 PT PT251624037T patent/PT4541381T/pt unknown
- 2018-09-25 LT LTEP25162390.6T patent/LT4541379T/lt unknown
- 2018-09-25 LT LTEP25162391.4T patent/LT4541380T/lt unknown
- 2018-09-25 IL IL319541A patent/IL319541B2/en unknown
- 2018-09-25 LT LTEP25162396.3T patent/LT4545101T/lt unknown
- 2018-09-25 KR KR1020267005571A patent/KR20260030955A/ko active Pending
- 2018-09-25 HR HRP20260100TT patent/HRP20260100T1/hr unknown
- 2018-09-25 KR KR1020257001675A patent/KR102932818B1/ko active Active
- 2018-09-25 SG SG11202100645XA patent/SG11202100645XA/en unknown
- 2018-09-25 ES ES25162394T patent/ES3064434T3/es active Active
- 2018-09-25 CN CN202511294533.XA patent/CN120860270A/zh active Pending
- 2018-09-25 PT PT251623906T patent/PT4541379T/pt unknown
- 2018-09-25 PL PL18783136.7T patent/PL3826686T3/pl unknown
- 2018-09-25 DK DK25162396.3T patent/DK4545101T3/da active
- 2018-09-25 KR KR1020217005212A patent/KR102643582B1/ko active Active
- 2018-09-25 FI FIEP25162396.3T patent/FI4545101T3/fi active
- 2018-09-25 JP JP2021504167A patent/JP7402218B2/ja active Active
- 2018-09-25 PT PT187831367T patent/PT3826686T/pt unknown
- 2018-09-25 SI SI201831307T patent/SI4545101T1/sl unknown
- 2018-09-25 RS RS20260085A patent/RS67667B1/sr unknown
- 2018-09-25 PL PL25162394.8T patent/PL4545100T3/pl unknown
- 2018-09-25 RS RS20260150A patent/RS67729B1/sr unknown
- 2018-09-25 EP EP25162391.4A patent/EP4541380B1/en active Active
- 2018-09-25 ES ES25162391T patent/ES3064589T3/es active Active
- 2018-09-25 DK DK18783136.7T patent/DK3826686T3/da active
- 2018-09-25 EP EP25162394.8A patent/EP4545100B1/en active Active
- 2018-09-25 FI FIEP18783136.7T patent/FI3826686T3/fi active
- 2018-09-25 PL PL25162391.4T patent/PL4541380T3/pl unknown
- 2018-09-25 RS RS20260183A patent/RS67755B1/sr unknown
- 2018-09-25 DK DK25162391.4T patent/DK4541380T3/da active
- 2018-09-25 HR HRP20260222TT patent/HRP20260222T1/hr unknown
- 2018-09-25 SI SI201831306T patent/SI4541380T1/sl unknown
- 2018-09-25 SI SI201831251T patent/SI3826686T1/sl unknown
- 2018-09-25 FI FIEP25162403.7T patent/FI4541381T3/fi active
- 2018-09-25 DE DE202018006567.6U patent/DE202018006567U1/de active Active
- 2018-09-25 DK DK25162403.7T patent/DK4541381T3/da active
- 2018-09-25 LT LTEP25162394.8T patent/LT4545100T/lt unknown
- 2018-09-25 HR HRP20260237TT patent/HRP20260237T1/hr unknown
- 2018-09-25 DE DE202018007007.6U patent/DE202018007007U1/de active Active
- 2018-09-25 WO PCT/IB2018/057415 patent/WO2020021322A1/en not_active Ceased
- 2018-09-25 PT PT251623914T patent/PT4541380T/pt unknown
- 2018-09-25 EP EP18783136.7A patent/EP3826686B1/en active Active
- 2018-09-25 PL PL25162396.3T patent/PL4545101T3/pl unknown
- 2018-09-25 HR HRP20250912TT patent/HRP20250912T1/hr unknown
- 2018-09-25 MX MX2021000805A patent/MX2021000805A/es unknown
- 2018-09-25 DK DK25162394.8T patent/DK4545100T3/da active
- 2018-09-25 FI FIEP25162394.8T patent/FI4545100T3/fi active
- 2018-09-25 IL IL319542A patent/IL319542B1/en unknown
- 2018-09-25 PL PL25162390.6T patent/PL4541379T3/pl unknown
- 2018-09-25 CA CA3153630A patent/CA3153630A1/en active Pending
- 2018-09-25 SI SI201831295T patent/SI4541379T1/sl unknown
- 2018-09-25 PT PT251623948T patent/PT4545100T/pt unknown
- 2018-09-25 DK DK25162390.6T patent/DK4541379T3/da active
- 2018-09-25 CN CN202511294891.0A patent/CN120860272A/zh active Pending
- 2018-09-25 DE DE202018007006.8U patent/DE202018007006U1/de active Active
- 2018-09-25 CN CN201880095724.5A patent/CN112584875A/zh active Pending
- 2018-09-25 LT LTEPPCT/IB2018/057415T patent/LT3826686T/lt unknown
- 2018-09-25 FI FIEP25162391.4T patent/FI4541380T3/fi active
- 2018-09-25 ES ES18783136T patent/ES3038413T3/es active Active
- 2018-09-25 CN CN202511294619.2A patent/CN121081692A/zh active Pending
- 2018-09-25 BR BR112021001148-0A patent/BR112021001148A2/pt unknown
- 2018-09-25 HR HRP20260179TT patent/HRP20260179T1/hr unknown
- 2018-09-25 EP EP25162390.6A patent/EP4541379B1/en active Active
- 2018-09-25 ES ES25162390T patent/ES3063402T3/es active Active
- 2018-09-25 RS RS20260182A patent/RS67754B1/sr unknown
- 2018-09-25 SI SI201831303T patent/SI4545100T1/sl unknown
- 2018-09-25 IL IL313560A patent/IL313560B2/en unknown
- 2018-09-25 RS RS20250737A patent/RS67034B1/sr unknown
- 2018-09-25 PT PT251623963T patent/PT4545101T/pt unknown
- 2018-09-25 EP EP25162396.3A patent/EP4545101B1/en active Active
-
2021
- 2021-01-20 MX MX2025012060A patent/MX2025012060A/es unknown
- 2021-01-20 CO CONC2021/0000506A patent/CO2021000506A2/es unknown
- 2021-01-20 IL IL280314A patent/IL280314A/en unknown
-
2022
- 2022-05-30 AU AU2022203683A patent/AU2022203683B2/en active Active
-
2023
- 2023-05-24 JP JP2023085193A patent/JP7796696B2/ja active Active
-
2024
- 2024-02-23 AU AU2024201217A patent/AU2024201217B2/en active Active
-
2025
- 2025-03-18 JP JP2025043874A patent/JP2025111424A/ja active Pending
- 2025-03-27 AU AU2025202231A patent/AU2025202231A1/en active Pending
- 2025-06-27 AU AU2025204901A patent/AU2025204901B2/en active Active
- 2025-08-22 AU AU2025220852A patent/AU2025220852B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12415003B2 (en) | Stable, concentrated radionuclide complex solutions | |
| US10596278B2 (en) | Stable, concentrated radionuclide complex solutions | |
| AU2024201217B2 (en) | Stable, concentrated radionuclide complex solutions | |
| US20210379213A1 (en) | Stable, concentrated radionuclide complex solutions | |
| HK40119657A (en) | Stable, concentrated radionuclide complex solutions | |
| HK40119656A (en) | Stable, concentrated radionuclide complex solutions | |
| HK40119654A (en) | Stable, concentrated radionuclide complex solutions | |
| HK40119655A (en) | Stable, concentrated radionuclide complex solutions | |
| HK40119658A (en) | Stable, concentrated radionuclide complex solutions | |
| HK40119658B (en) | Stable, concentrated radionuclide complex solutions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20230925 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20240823 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240823 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240823 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240823 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20241220 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250211 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250424 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250424 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD Year of fee payment: 7 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250819 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250819 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20260128 |